These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2122652)

  • 21. Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease.
    Bravi D; Anderson JJ; Dagani F; Davis TL; Ferrari R; Gillespie M; Chase TN
    Mov Disord; 1992; 7(3):228-31. PubMed ID: 1620140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease.
    Olanow CW; Fahn S; Muenter M; Klawans H; Hurtig H; Stern M; Shoulson I; Kurlan R; Grimes JD; Jankovic J
    Mov Disord; 1994 Jan; 9(1):40-7. PubMed ID: 8139604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Parkinson disease--problems in long-term treatment. Dopamine agonists optimize L-dopa therapy].
    Fuchs G
    Fortschr Med; 1997 Feb; 115(5):43-5. PubMed ID: 9162718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of carbidopa as an adjuvant to levodopa/carbidopa therapy in patients with Parkinson's disease.
    Lieberman AN; Gopinathan G; Neophytides A; Pasternack P
    N Y State J Med; 1986 Dec; 86(12):655-6. PubMed ID: 3468386
    [No Abstract]   [Full Text] [Related]  

  • 25. Long-term efficacy of controlled-release carbidopa/levodopa in patients with advanced Parkinson's disease.
    Mark MH; Sage JI
    Ann Clin Lab Sci; 1989; 19(6):415-21. PubMed ID: 2690730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The dopamine agonist, lisuride, in the therapy of Parkinson disease].
    Madeja UD
    Acta Histochem Suppl; 1992; 42():25-31. PubMed ID: 1584973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term effect of levodopa on progression of Parkinson's disease.
    Webster DD; Mortimer JA; Kuskowski MA
    Adv Neurol; 1987; 45():473-6. PubMed ID: 3103390
    [No Abstract]   [Full Text] [Related]  

  • 28. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis.
    Merello M; Nouzeilles MI; Arce GP; Leiguarda R
    Mov Disord; 2002 Jul; 17(4):795-8. PubMed ID: 12210878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Lisuride in the combination treatment of Parkinson disease].
    Jellinger K
    Wien Med Wochenschr; 1987 Apr; 137(7-8):155-9. PubMed ID: 3111099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study.
    Pahwa R; Marjama J; McGuire D; Lyons K; Zwiebel F; Silverstein P; Ward R; Koller WC
    Mov Disord; 1996 Jul; 11(4):427-30. PubMed ID: 8813223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Motor response complications with chronic levodopa therapy.
    Chase TN; Fabbrini G; Juncos JL; Mouradian MM
    Adv Neurol; 1990; 53():377-81. PubMed ID: 2239478
    [No Abstract]   [Full Text] [Related]  

  • 32. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease.
    Stocchi F; Ruggieri S; Vacca L; Olanow CW
    Brain; 2002 Sep; 125(Pt 9):2058-66. PubMed ID: 12183351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years.
    Hughes AJ; Bishop S; Kleedorfer B; Turjanski N; Fernandez W; Lees AJ; Stern GM
    Mov Disord; 1993 Apr; 8(2):165-70. PubMed ID: 8474483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Parkinson's disease and long-term levodopa therapy.
    Bergmann KJ; Mendoza MR; Yahr MD
    Adv Neurol; 1987; 45():463-7. PubMed ID: 3103389
    [No Abstract]   [Full Text] [Related]  

  • 35. Problems in daily motor performances in Parkinson's disease: the continuous dopaminergic stimulation.
    Stocchi F; Ruggieri S; Brughitta G; Agnoli A
    J Neural Transm Suppl; 1986; 22():209-18. PubMed ID: 3465872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
    Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Combined therapy of carbidopa and levodopa in Parkinson's disease].
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):201-4. PubMed ID: 4075908
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of controlled-release carbidopa/levodopa on motor performance in advanced Parkinson's disease.
    Rondot P; Ziegler M; Aymard N; Teinturier A
    Neurology; 1989 Nov; 39(11 Suppl 2):74-7; discussion 95. PubMed ID: 2586765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lisuride infusion pump for Parkinson's disease.
    Lancet; 1986 Aug; 2(8502):348-9. PubMed ID: 2874360
    [No Abstract]   [Full Text] [Related]  

  • 40. Chronic s.c. lisuride in Parkinson's disease--motor-performance and avoidance of psychiatric side effects.
    Bittkau S; Przuntek H
    J Neural Transm Suppl; 1988; 27():35-54. PubMed ID: 3165438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.